These companies have approved Alzheimer's treatments that could generate billions in revenue for their respective businesses.One thing that can help with the treatment of any disease is early detection, and Alzheimer's is no exception to that. And the good news is that in the near future, detecting cases of Alzheimer's disease could simply involve a blood test.A new wave of blood tests involves checking for p-tau217, which is an abnormal protein that can help accurately detect 90% of Alzheimer's cases. The ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 0-19311 BIOGEN INC. (Exact name of registrant as specified in its charter) Delaware 33-0112644 (State or other jurisdiction of incorporation or organization)(I.R.S. Employer Iden ...

Biogen (BIIB) reported second-quarter 2024 adjusted earnings per share (EPS) of $5.28, beating the Zacks Consensus Estimate of $4.00. Earnings rose 31% year over year. Earnings benefited from the sale of one of Biogen's two priority review vouchers (PRV). Excluding PRV sales, adjusted earnings rose 18% in the quarter.Total revenues came in at $2.47 billion, flat on a reported basis and up 1% on a constant-currency basis from the year-ago quarter as lower sales of key multiple sclerosis (MS) drugs like Tecfi ...

Biogen Inc. (NASDAQ:BIIB) Q2 2024 Earnings Call Transcript August 1, 2024 8:30 AM ET Company Participants Chuck Triano - Head of IR Chris Viehbacher - President and CEO Alisha Alaimo - Head and President of North America Priya Singhal - Head of Development Travis Murdoch - Head of HI-Bio Mike McDonnell - CFO Conference Call Participants Salveen Richter - Goldman Sachs Evan Seigerman - BMO Capital Markets Michael DiFiore - Evercore ISI Nicole Gabreski - Piper Sandler Paul Matteis - Stifel Michael Yee - Jeffe ...

Biogen Inc. (BIIB) reported $2.46 billion in revenue for the quarter ended June 2024, representing a year-over-year increase of 0.4%. EPS of $5.28 for the same period compares to $4.02 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $2.38 billion, representing a surprise of +3.54%. The company delivered an EPS surprise of +32.00%, with the consensus EPS estimate being $4.00.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stree ...

Biogen Inc. (BIIB) came out with quarterly earnings of $5.28 per share, beating the Zacks Consensus Estimate of $4 per share. This compares to earnings of $4.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 32%. A quarter ago, it was expected that this company would post earnings of $3.45 per share when it actually produced earnings of $3.67, delivering a surprise of 6.38%.Over the last four quarters, the company has surpass ...

| --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|-----------------------------------------------------------|-------|----------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Second Quarter 2024 Financial Results and Business Update | | | | | | | | | | | | | | | | | | | | August 1, 2024 | | Non-GAAP financial information This presentation and the discussions during this conference call include certain finan ...

A test tube is seen in front of displayed Biogen logo in this illustration taken on, December 1, 2021.Biogen on Thursday reported second-quarter earnings and revenue that topped estimates and hiked its full-year guidance, as the company's cost cuts showed progress and sales of its breakthrough Alzheimer's drug, Leqembi, and other new products beat expectations. Biogen now expects full-year adjusted earnings to come in at $15.75 to $16.25 per share, up from a previous forecast of $15 to $16 per share.The bio ...

Press Release Cambridge, Mass. – Aug. 1, 2024 Biogen reports strong second quarter 2024 results and raises full year 2024 financial guidance; Second quarter 2024 total revenue of $2.5 billion, GAAP diluted EPS of $4.00 and Non-GAAP diluted EPS of $5.28 Second quarter total revenue was flat at actual currency and up 1% at constant currency, with GAAP diluted EPS decline of 2% and Non-GAAP diluted EPS increase of 31% year-over-year • Core pharmaceutical revenue (product revenue + LEQEMBI) up 5% at actual curr ...

Alcyone's ThecaFlex is an implantable medical device under investigation for routine subcutaneous administration of therapeutics to the cerebrospinal fluid (CSF). The first stage of the pivotal IDE PIERRE trial has been completed. 10 spinal muscular atrophy (SMA) patients have undergone ThecaFlex implantation and have received nusinersen through the device. No device-related adverse events, including infections, were observed in the 30 days after implantation. FDA has agreed to an additional 80-SMA patient ...